Liver Cancer

Hepatocellular carcinoma (HCC) often arises in chronic viral hepatitis, MAFLD, and cirrhosis, engaging TERT promoter, TP53, CTNNB1/AXIN1, and angiogenic programs. We provide AFP/GPC3 biomarker antibodies and multi-kinase / mTOR / PI3K probes for TME, resistance, and combinations.

Focus areas: clonal evolution in cirrhosis, angiogenesis & immunotherapy, bile acid–immune axis, portal vein tumor thrombus models

Liver cancer–related antibodies (curated)

Loading…

Hot topics & directions

  • First-line systemic stratification: AFP kinetics, imaging response, longitudinal ctDNA concordance.
  • Anti-angiogenic + IO: VEGF-axis remodeling vs T-cell infiltration timing.
  • WNT/β-catenin subtype: Immune-excluded biology in CTNNB1-mutant contexts.
  • Translational biobanking: Standardized triad processing (tumor/adjacent/plasma).

Related targets

WNT / HCC drivers
CTNNB1, AXIN1, APC, TCF7L2
TP53 / cell cycle
TP53, CDKN2A, RB1, MDM2
Angiogenesis
VEGFA, KDR, FLT1, PDGFB, ANGPT2
Checkpoint / metabolism
CD274, PDCD1, CTLA4, LAG3, IDO1

Key signaling pathways

  1. WNT–β-catenin
    Canonical subtype driver; often inversely correlated with immune infiltration.
  2. VEGF/PDGF 血管重塑
    Core anti-angiogenesis axis; couples to hypoxia/EMT.
  3. PI3K–AKT–mTOR
    Survival/anabolism intersecting with cirrhotic metabolism.
  4. TGF-β / 纤维化
    Matrix stiffening & immune suppression; bidirectional progression.

Tool compounds (research use)

Commonly used for mechanistic studies; follow your lab SOP, compound datasheets, and ethics approvals.

CompoundTargets / pathwaysExperimental notes
SorafenibMulti-kinase (VEGFR/RAF, etc.)Classic systemic probe; log HFSR/hypertension.
LenvatinibVEGFR1–3 / FGFR / PDGFR, etc.First-line alternative mapping; TFTs/proteinuria.
RegorafenibMulti-kinaseSecond-line resistance models; combo toxicity matrices.
CabozantinibMET/VEGFR/AXL, etc.Invasion/TME remodeling readouts.
EverolimusmTORC1mTOR-dependency validation; mind immunosuppression.
ApatinibVEGFR2 (research contexts)Alternative VEGFR2 small-molecule; verify animal PK.
MK-2206AKT1/2/3PI3K/AKT validation; sequential readouts with sorafenib.